Compare HubSpot Inc (HUBS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Merck & Co., Inc. — how do they compare? HubSpot Inc trades at $229.3 (market cap $11.56B), while Merck & Co., Inc. trades at $146.1 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 30.4× HubSpot Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Merck & Co., Inc. for 98 Days on average.
| HUBS | MRK | |
|---|---|---|
Market Cap | $11.56B | $351.28B |
Volume | 1,891,287 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $494.58 | $156.43 |
52-Week Low | $170.39 | $82.49 |
Typical Hold Time | 78 Days | 98 Days |
Enterprise Value | $10.46B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.30, up 3.63% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with improving profitability, though valuation ratios remain elevated. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though risks include high P/E ratio, competitive pressures, and potential AI disruption concerns. The stock offers growth exposure with solid cash flow generation but requires monitoring of execution against ambitious margin targets.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
